Nightstar Receives Orphan Drug Designation for Gene Therapy to Treat Choroideremia
Nightstar has received FDA and European Medicines Agency Orphan Drug Designation for its gene therapy to treat choroideremia, an X-linked recessive disorder that leads to progressive blindness, according to a company news release.
Orphan Drug Designation, intended to facilitate drug development for rare diseases, provid...